Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Long-term results of radio(chemo)therapy in metastatic carcinoma to cervical lymph nodes from an unknown primary. Adult Comorbidity Evaluation 27 score as a predictor of survival

M. Pala, P. Novakova, Z. Pechacova, L. Vesela, A. Vrana, J. Sukova, P. Holeckova, T. Drbohlavova, T. Podlesak, L. Petruzelka

. 2023 ; 199 (2) : 149-159. [pub] 20220809

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004456
E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2006-08-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 1997-01-01 do Před 1 rokem

PURPOSE: To evaluate the effectiveness and toxicity of curative (chemo)radiotherapy in patients with metastatic carcinoma to cervical lymph nodes from an unknown primary. METHODS: Retrospective study of 90 consecutive patients, treated with curative radiotherapy from 2003 to 2018 (median age 59 years; current/former smokers 76%) was conducted. The distribution of nodal staging was as follows: N1: 12%, N2a: 21%, N2b: 43%, N2c: 10%, N3: 13%. In 62% of patients, neck dissection was performed before radiotherapy. Concomitant chemotherapy was given to 64% of patients. RESULTS: The median follow-up of surviving patients was 86 months. The median total radiotherapy dose achieved was 70 Gy. The 5‐ and 10-year locoregional control were 84% in both cases, while 5‐ and 10-year distant control were 90% and 89%, respectively. A primary tumor in the head and neck area was detected in only 2 patients. No patient had an initial failure in the pharyngeal axis or contralateral cervical nodes. The 5‐ and 10-year overall survival were 55% and 42%, respectively. Severe early toxicity occurred in 71%; severe late toxicity in 33% of patients. Multivariate analysis demonstrated N‐status (hazard ratio [HR] 2.424; 95% confidence interval [CI] 1.121-5.241; p = 0.024) and comorbidity scores assessed by ACE-27 (Adult Comorbidity Evaluation; HR 3.058; 95% CI 1.489-6.281; p = 0.002) as two independent prognostic factors for overall survival. CONCLUSION: The results of our work study demonstrate the high effectiveness of curative (chemo)radiotherapy on the pharyngeal axis and bilateral cervical nodes with long-term locoregional and distant control in 3/4 of the treated patients. N‐status and comorbidity scores were shown as strong prognostic factors influencing overall survival.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004456
003      
CZ-PrNML
005      
20230425141419.0
007      
ta
008      
230418s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00066-022-01983-6 $2 doi
035    __
$a (PubMed)35943554
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Pala, Miloslav $u Institute of Radiation Oncology of the 1st Faculty of Medicine Charles University, Bulovka University Hospital, Budínova 2, 18001 Praha 8, Prague, Czech Republic. miloslav.pala@bulovka.cz $1 https://orcid.org/0000000284466339 $7 xx0088087
245    10
$a Long-term results of radio(chemo)therapy in metastatic carcinoma to cervical lymph nodes from an unknown primary. Adult Comorbidity Evaluation 27 score as a predictor of survival / $c M. Pala, P. Novakova, Z. Pechacova, L. Vesela, A. Vrana, J. Sukova, P. Holeckova, T. Drbohlavova, T. Podlesak, L. Petruzelka
520    9_
$a PURPOSE: To evaluate the effectiveness and toxicity of curative (chemo)radiotherapy in patients with metastatic carcinoma to cervical lymph nodes from an unknown primary. METHODS: Retrospective study of 90 consecutive patients, treated with curative radiotherapy from 2003 to 2018 (median age 59 years; current/former smokers 76%) was conducted. The distribution of nodal staging was as follows: N1: 12%, N2a: 21%, N2b: 43%, N2c: 10%, N3: 13%. In 62% of patients, neck dissection was performed before radiotherapy. Concomitant chemotherapy was given to 64% of patients. RESULTS: The median follow-up of surviving patients was 86 months. The median total radiotherapy dose achieved was 70 Gy. The 5‐ and 10-year locoregional control were 84% in both cases, while 5‐ and 10-year distant control were 90% and 89%, respectively. A primary tumor in the head and neck area was detected in only 2 patients. No patient had an initial failure in the pharyngeal axis or contralateral cervical nodes. The 5‐ and 10-year overall survival were 55% and 42%, respectively. Severe early toxicity occurred in 71%; severe late toxicity in 33% of patients. Multivariate analysis demonstrated N‐status (hazard ratio [HR] 2.424; 95% confidence interval [CI] 1.121-5.241; p = 0.024) and comorbidity scores assessed by ACE-27 (Adult Comorbidity Evaluation; HR 3.058; 95% CI 1.489-6.281; p = 0.002) as two independent prognostic factors for overall survival. CONCLUSION: The results of our work study demonstrate the high effectiveness of curative (chemo)radiotherapy on the pharyngeal axis and bilateral cervical nodes with long-term locoregional and distant control in 3/4 of the treated patients. N‐status and comorbidity scores were shown as strong prognostic factors influencing overall survival.
650    _2
$a lidé $7 D006801
650    _2
$a dospělí $7 D000328
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádory neznámé primární lokalizace $x terapie $x patologie $7 D009382
650    _2
$a retrospektivní studie $7 D012189
650    12
$a nádory hlavy a krku $x patologie $7 D006258
650    _2
$a lymfatické metastázy $x patologie $7 D008207
650    12
$a karcinom $x patologie $7 D002277
650    _2
$a lymfatické uzliny $x patologie $7 D008198
650    _2
$a staging nádorů $7 D009367
655    _2
$a časopisecké články $7 D016428
700    1_
$a Novakova, Pavla $u Radiophysics Department, Bulovka University Hospital, Prague, Czech Republic
700    1_
$a Pechacova, Zdena $u Institute of Radiation Oncology of the 1st Faculty of Medicine Charles University, Bulovka University Hospital, Budínova 2, 18001 Praha 8, Prague, Czech Republic
700    1_
$a Vesela, Lucie $u Institute of Radiation Oncology of the 1st Faculty of Medicine Charles University, Bulovka University Hospital, Budínova 2, 18001 Praha 8, Prague, Czech Republic
700    1_
$a Vrana, Antonin $u Institute of Radiation Oncology of the 1st Faculty of Medicine Charles University, Bulovka University Hospital, Budínova 2, 18001 Praha 8, Prague, Czech Republic
700    1_
$a Sukova, Jarmila $u Institute of Radiation Oncology of the 1st Faculty of Medicine Charles University, Bulovka University Hospital, Budínova 2, 18001 Praha 8, Prague, Czech Republic
700    1_
$a Holeckova, Petra $u Institute of Radiation Oncology of the 1st Faculty of Medicine Charles University, Bulovka University Hospital, Budínova 2, 18001 Praha 8, Prague, Czech Republic
700    1_
$a Drbohlavova, Tereza $u Institute of Radiation Oncology of the 1st Faculty of Medicine Charles University, Bulovka University Hospital, Budínova 2, 18001 Praha 8, Prague, Czech Republic
700    1_
$a Podlesak, Tomas $u Department of Otorhinolaryngology, Bulovka University Hospital, Prague, Czech Republic
700    1_
$a Petruzelka, Lubos $u Institute of Radiation Oncology of the 1st Faculty of Medicine Charles University, Bulovka University Hospital, Budínova 2, 18001 Praha 8, Prague, Czech Republic $u Department of Oncology of the 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
773    0_
$w MED00010658 $t Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] $x 1439-099X $g Roč. 199, č. 2 (2023), s. 149-159
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35943554 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141415 $b ABA008
999    __
$a ok $b bmc $g 1924882 $s 1190665
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 199 $c 2 $d 149-159 $e 20220809 $i 1439-099X $m Strahlentherapie und Onkologie $n Strahlenther Onkol $x MED00010658
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...